ïŒç¶ãïŒ
以äžãQ&Aããã
Q.ã¢ã³ã±ãŒããéã£ãŠãååãåŸãããªãå Žåã¯ã©ãããã°ãããïŒ
A.掻çšã§ããæ
å ±ãæ¢ãããèªåã§æž¬å®ããã
Q.å
è£
è³æã®ãªã¹ã¯ã¢ã»ã¹ã¡ã³ãã¯ã©ãããã°ãããïŒ
A1.å
è£
è³æã®Root causeã¯ãããã»ã«ããŒã¹ç±æ¥ã§ãããã¯ãŒã¹ãã±ãŒã¹ã§ãæ··å
¥ãªã¹ã¯ã¯äœããïŒã¡ããã«ãã³ã®æ§ã«ïŒå€§éã«æåãã補å€ã§ããåé¡ã«ãªããªããšèãããMitigationæ¹æ³ãšããŠã¯ãããã»ã«ããŒã¹ãä»æåã«å€æŽããããšã ããä»æ¬åœã«å€ããå¿
èŠãããããããæ€èšããããšãéèŠãããããç³è«ãã補åã§ããã°å€æŽããã°ããããŸããã³ãã¬ãŒã·ã§ã³ã«ããå
è£
æã®ææ°ãååã«è¡ãããšãæå¹ãšèããã
A2.ãããã»ã«ããŒã¹ã«ããããããœååå¿ã®è©³çŽ°ã«ã€ããŠã¯æ£çŽblack boxã§ãããã¡ããã«ãã³ã®äºäŸã§ã¯APIäžã®æ®çã¢ãã³ã«ããé å€è¡šé¢ã§ããããœååå¿ãèµ·ãã£ããšèãããããã·ãŒãªã³ã°ããã»ã¹ã®èŠçŽãçãèãããããããã¯ã倧ããªãªã¹ã¯ã§ã¯ãªãã®ã§ãå€æŽãçŸå®çãã©ãããèæ
®ããŠã±ãŒã¹ãã€ã±ãŒã¹ã§å¯Ÿå¿ããã
Q.補å€ã§äœ¿çšããæ°Žã®ãªã¹ã¯ã¢ã»ã¹ã¡ã³ãã¯ã©ãããïŒ
A1.APIã§ã®ãªã¹ã¯ã¯äœããããã«å¯ŸããŠè£œå€è£œé äžã®é ç²æçã«äœ¿çšããæ°Žã«ããããããœã¢ãã³ã®æ··å
¥ãªã¹ã¯ã«ã€ããŠã¯ã詳现ãããŸãç¥ãããŠããªããããããæ
å ±ãåºãŠãããšæãããå°ãæéãããããšæãã
Q.ãªã¹ã¯ã¢ã»ã¹ã¡ã³ãã¯ã©ããŸã§å®æœããã®ãïŒåæã¯å¿
é ãªã®ãïŒ
A1.ã±ãŒã¹ãã€ã±ãŒã¹ãšãããããªãããäºç¡é
žãïŒäœçŽïŒäºçŽã¢ãã³çã®ç©æ§ã¯ããç¥ãããŠããã®ã§ãå¿
ãããåæã¯å¿
é ã§ã¯ãªããšèããã
A2.åœå
ã§ã¯ãŸã ãŸã ç¥èŠãååã§ã¯ãªãããå¿
é ã§ã¯ãªããšèãããéã«åæçµæãããã°ãããšãããã®ã§ããªããããŒãžãã¡ã¯ã¿ãŒãçšããæ€èšãæçšãšèšããã
A3.å»è¬å補é ã«ã©ãããŠãã¢ãã³æºã¯ååšãããEUã§ã¯60äžã®å»è¬åãåžå Žã«ååšããããšããããããã®å
šãŠã«ã€ããŠè©Šéšãããããšã¯äžå¯èœãAPIã§ã¯ç§åŠçèå¯ãããŒãžãã¡ã¯ã¿ãŒçãæå¹ã«äœ¿ããè©Šéšã§ã¯ãªããŠãå質ã確èªããããšãã倧äºã
A4.GMPã¯GMPãšããŠåããŠèãããã³ã³ã¿ãçã®GMPã®åé¡ã¯GMPã§ãã¡ããšå¯Ÿå¿ãããäºçŽã¢ãã³ãçšããŠããå ŽåããäžçŽã¢ãã³äžã«äžçŽç©ãšããŠäºçŽã¢ãã³ãååšããå Žåçã§ãããããœã¢ãã³ã®æ··å
¥ãäºæž¬ã§ãããã®ã«ã€ããŠã¯ãé©åã«å¯Ÿå¿ããã
Q.æªç¥ããããœã¢ãã³ïŒNDSRIïŒã¯18ng/dayãšãããããªãŒãã¢ã¯ãã¹ããããïŒ ã·ã¿ã°ãªããã³ã§ã¯EMAãšFDAã§é床å€ãç°ãªã£ãŠããïŒ37ng/dayãš246.7 ng/dayïŒã
A1.ããšãã·ã³ãã«ãªæ§é ã§ãã£ãŠããå€ãã®ããããœã¢ãã³ã§ã¯é å¥ãªå®å
šæ§ããŒã¿ããªãã®ãçŸç¶ãçŸæç¹ã§ã¯AIç®åºæ¹æ³ã«ã€ããŠåæã«è³ãã®ãé£ããããŸã ãŸã 1ïœ3幎çšåºŠãããããšããããtemporary AIã§1幎éã¯æéã皌ããã
A2.EMAã§ãä»ã®èŠå¶åœå±ãšé 匵ã£ãŠèª¿æŽããŠããããååžå Žåºæã®åé¡ãèãæ¹ã®éãçããããglobalãªèª¿åã«ã¯æéãããããçŸåšEMAã§ã¯åŠè¡æ©é¢ã«å§èšããŠç 究ãé²ããŠãããé å¥ãªå®å
šæ§ããŒã¿ã®ååŸãé床ã«ä¿å®çã§ãªããªãŒãã¢ã¯ãã¹æ³ã®æ§ç¯ã«åãçµãã§ããã
A3.αäœã®ãããã³ããªããã®ã¯Cohort of Concernã§ãªããŠãããšèãããæ§é é¡äŒŒæ§ã»ä»£è¬ã¡ã«ããºã çãååã«èæ
®ããã
Q.NDSRIã«ã€ããŠãåœé調åã¯ã©ããªã£ãŠããã®ãïŒ
A1.çºããæ§ããŒã¿ã®ãªãããããœã¢ãã³ã«ã€ããŠã¯ãçºããæ§ã®åŒ·ããæ°å€ãçšããŠå®éåã§ããªãããšãåé¡ãåè°ã¯ããŠããããµã€ãšã³ã¹ã確ç«ãããŠããªããçµè«ãåºãã®ã¯æ©ããšã2024幎ã®åããããã«ã¯ãªãã®ã§ã¯ãªããã
A2.PMDAã¯ãªãœãŒã¹ã足ããŠããªããM7ã§ã¯ãµãã²ãŒããå€ãããããããœã¢ãã³ã§ã¯ãµãã²ãŒããéãããŠãããããã©ãããŠãçºããæ§ãããšããåæã§é²ããããåŸãªãããŸãPotencyã®åŒ·ããè°è«ã§ããªããããçŸç¶ããããŒã¿ãçšããŠread-acrossããããšã«ãªã£ãŠããŸãã
Q.FDAã§èšã£ãŠããMitigationã«ã€ããŠæããŠã»ãããWHOã®NAPãã¹ãã¯å¿
èŠãïŒè£œæ³ãå€ãããåŠæ¹ãå€ããçã®ã¢ãããŒãããããå®éã®ãšããã¯ã©ããïŒ
1.æ·»å å€äžã®äºç¡é
žå¡©ãæžããåãçµã¿ã¯é²ããããŠãããæ±çšãããŠãããã®ã«ã€ããŠã¯ä»åŸ1ppm以äžã«ããããšãéæã§ãããšèãããããã1ppm以äžã§ãååãšã¯èšããªãã®ãçŸç¶ãã¹ã«ãã³ãžã£ãŒãå
¥ããããšãèšãããŠããããããã«ãã補å€å
šäœãžã®åœ±é¿ã¯äžæã§ãããããšãããããœã¢ãã³ãæžããããšããŠãå¥ã®ãã¬ãã£ããªåœ±é¿ããããããããªããæ«å®187ng/dayãããŸã掻çšããŠé²ããã®ãããã
2.ã¹ã«ãã³ãžã£ãŒã¯ããºã«ã®1ããŒã¹ã®ããã«ä»ã®èŠçŽ ãšè€éã«çµ¡ã¿åã£ãŠããããã®ããå®éã«è¡ããšãªããšãpHå€ããã湿åŒé ç²ãæ¢ãããåŠæ¹ãå€ãããããŒã¿ãååŸããŠãªããªããŒã·ã§ã³ãå®æž¬ããŒã¿ååŸçãæ°å€ãã®æ®µéãååšããããŸãããã®çµæãäžçŽç©ãå€ãã£ãŠããŸããããããªããæéãæããŠè°è«ãç¶ããŠãå®å
šæ§ãèæ
®ããªããå°ããã€Mitigationæ¹æ³ã®æ¹åãç¶ããŠãããããªãã
以äžã§ãã
åŸæ¥ãéå¶åŽããææžãšããŠå
¬éããããšæããŸãã®ã§ãæ£åŒçã¯ãã¡ãããåŸ
ã¡ãã ããã
3 Likes
Do you think we could have access to the details of the method that was referenced by Prof. Uchiyama?
1 Like
Do you think we could get access to the presentations?, it seems like great case studies⊠Thanks for sharing all the great insights!
1 Like
Hi, @Naiffer_Host .
We received Dr. Uchiyamaâs slides today. I share references for her presentation.
NDMA in Valsartan
NDMA in Ranitidine
SPE-LC-MS/MS
2 Likes
Yes, Dr. Nagatoâs presentation is excellent. However, it includes lots of Japanese words. I think it is too difficult to translate into English.
The PDA team posted the report to the âPDA Journal of GMP and Validation in Japanâ last time. When the report for this year discloses, I will share the link.
2 Likes
ããã«ã¡ããæ¥æ¬ã®çæ§
10/21ã®å€ç°ååŠäŒã® ICH M7/QSARã¯ãŒã¯ã·ã§ããã¯ã200人以äžã®åå ããããè°è«ãçãäžãã£ãŠéåžžã«ææ矩ã§ãããå
çã«è¬æŒè³æã®å
±æãé²ããŠè²°ã£ãŠããŸãã®ã§ãå°ã
ãæéãããã ããã°ãšæããŸãã
ããŠãè¬æŒå
ã§ãã£ã倧æ°äžã®NOxã¬ã¹ã®åœ±é¿ã«ãããæµåå±€é ç²æã®ããããœã¢ãã³åœ¢æã®åé¡ ã§ããã調ã¹ãŠã¿ããšãã以äžã«é¢é£ããã¹ã¬ããããããŸããã
We had a very interesting laboratory investigation last year on Nitrosamines.
Generally when we talk about Nitrosamines, we end up talking about APIs, Water and associated solvents being used.
However, we had an investigation where the environment (air) was a source of NOx leading to generation of impurities in the APIs.
No laboratory error or phase-II error could be identified for an OOS sartan API; the manufacturer claimed there was no NDEA / NDMA in their control samples which they broughtâŠ
ãã¡ãã¯è©³çŽ°ãªæ¡ä»¶ã¯äžæã§ãããããããœã¢ãã³ãå«ãŸãªããµã«ã¿ã³APIããä¿ç®¡äžã«ããããœã¢ãã³ã®æ··å
¥ãèªãããšã®ããšã§ã倧æ°äžã®NOxã¬ã¹ã®åœ±é¿ãæžå¿µããŠãããå
è£
ã®é©åæ§ïŒLDPEçãééæ§ã®ãããã®ãé¿ããïŒã«ã€ããŠèšåããŠããŸããDMAãTEAçã®ã¢ãã³ã®èµ·æºã«ã€ããŠã¯äžæã§ãã
æµåå±€é ç²æã¯æ°Žã䜿ããç±ããããããšãããç¹ã«äºçŽã¢ãã³ãå«ãåè¬ã§ããã€å¡©é
žå¡©çã§pHãé
žæ§ã«ãªãå Žåã¯ãå€æ°ããåã蟌ãŸãã倧éã®ç©ºæ°ã«å«ãŸããNOxã¬ã¹ã®åœ±é¿ã¯ã倧ããªãªã¹ã¯ãšãªãå¯èœæ§ããããŸããä»ã®å»è¬åã«ãããŠãåæ§ã«ãªã¹ã¯ãšãªãã®ããæŽãªã調æ»ãå¿
èŠã§ããã
heajin
October 24, 2022, 10:19pm
38
Thank you so much for sharing these valuable information! It could be a great help for all of us who are working for the nitrosamine issues.
I was wondering if you can provide more information on this new strategy to set AI of NDSRIs presented by @AndyTeasdale @AZ
[quote=âYosukemino, post:31, topic:1626â]
ã»æ°ããAIèšå®ã®ã¯ãŒã¯ãããŒã®ææ¡ããã£ãïŒ 1. α-æ°ŽçŽ ã®æç¡ïŒïŒNoã§scopeå€ïŒ2. Amesè©Šéšã§éœæ§ïŒïŒNoã§1.5ug/day以äžïŒ3.α-ççŽ ã¯äž¡æ¹ãšãCH2ã§ã¯ãªãïŒïŒYesã§500ng/day以äžïŒ 4.α-ççŽ ã®äžæ¹ãã¡ãã«ãŸãã¯ãšãã«ã§ãå察åŽãè³éŠç°ã§ã¯ãªã çïŒYesã§100ng/day以äžïŒ5. ããããœã¢ãã³ãããºãªãžã³ç°ããŒã¹ïŒïŒYesã§1300ng/day以äžïŒ6.ååé200ãã倧ã§150ng/day以äž
[/quote].
Thank you!
Hi, @heajin .
Thank you for asking. I shared the workflow suggested by @AndyTeasdale . Itâs excellent!! I hope it will be officially used in the future.
heajin
October 26, 2022, 6:29am
40
Hi @Yosukemino
Thank you so much for sharing this slide!
I guess
1500 ng/day comes from TTC 1.5 ug/day
100 ng/day comes from AI of NNK (EMA QnA)
1300 ng/day comes from AI of NPIP (EMA QnA)
I was wondering⊠where did other two limits, â500 ng/dayâ for both side of nitrosamine lack a CH2 alpha and â150 ng/dayâ for all the other NDSRIs with MW > 200 ??
I guess itâs a similar strategy to the article, âPractical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product N -Nitrosamine Impurities â. The limits do not come from a single compound but from the surrogate such as the lowest one in the group, I think.
@AndyTeasdale , I would appreciate it if you could help us.
@AndyTeasdale was having issue with his logging, but it has been resolved. Thanks
1 Like
æ¥æ¬ã®çããŸ
æ¬æ¥ãæ¥æ¬åœå
ã®Q&AãçºåºãããŸãããé¢ä¿è
ã®çããŸããç²ãæ§ã§ããã
ãªããQ6ã¯ä»¥äžã®ããã«ãªã£ãããã§ãã
Q6. åè¬è¥ããã¯è£œå€ã®è£œé åã¯å
è£
ã«ä¿ã補é æ¥è
åã³æ·»å å€ãè©Šè¬ã容åšæœæ ç³»çã®äŸçµŠæ¥è
ããé©åãªæ
å ±é瀺ããªãå Žåãããããœã¢ãã³é¡ã®æ··å
¥ãªã¹ã¯è©äŸ¡ã¯ã©ã®ããã«è¡ãã°ãããã
A6. å»è¬åã®è£œé 販売æ¥è
ã¯ãå»è¬åã®å質ãæå¹æ§åã³å®å
šæ§ã«äžãã圱é¿äžŠã³ã«äººã®å¥åº·ã«äžãã圱é¿ã«é¢ããé©æ£ãªè©äŸ¡ãè¡ãå¿
èŠãããããšãããå¿
èŠãªæ
å ±ãå
¥æããããšããªãããããåŸãªãçç±ã«ããå¿
èŠãªæ
å ±ã®äžéšã«ã€ããŠå
¥æã«æéãèŠããå ŽåãåŸãããŠããæ
å ±ã«åºã¥ãæ«å®çãªè©äŸ¡ãå®æœããååãªæ
å ±ã«åºã¥ãè©äŸ¡ãšåºå¥ã§ãã圢ã§ææžåããçãé©åã«å¯Ÿå¿ããããš ã
2 Likes
æ¥æ¬ã®çæ§ é
ãã°ããªãããããŸããŠããã§ãšãããããŸãã
æ¬å¹Žãã©ãããããããé¡ãããããŸãã
ããŠãæ¥æ¬ã«ããããªã¹ã¯è©äŸ¡ïŒStep1ïŒã®ç· ãåããä»å¹Žã®4/30æ¥ã«è¿«ã£ãŠããŠããŸãããé²æã¯ãããã§ããããïŒ
ç§ã¯æã
ããããœã¢ãã³ã«é¢ããŠè¬æŒããããã¡ãŒã«ã§è³ªåãããã ããŠãŸããããã¯ãæ¥æ¬åœå
ã®å€ãã®æ¹ã
ããªã¹ã¯è©äŸ¡ã«ãããŠçåããã£ãããäžå®ãæããŠããããã«æããŸãã
å
æQ&Aã¯çºåºããããã®ã®ããŸã ãŸã æ¥æ¬åœå
ã§ã®æ
å ±å
±æãè°è«ã足ããŠããªãã®ããšæã£ãŠããŸãã
ããã§ãããã€ãã®å£äœã«ãé¡ãããŠãç· ãåããŸã§ã«ãªã¹ã¯è©äŸ¡ã«é¢ããã©ãŠã³ãããŒãã«åœ¢åŒã®ãªã³ã©ã€ã³èšè«äŒãéå¬ããããšãèšç»ããŠããŸãã
è¡šé¡ïŒããããœã¢ãã³ãªã¹ã¯è©äŸ¡ã°ã«ãŒãèšè°ïŒ20åçšåºŠïŒïŒ
ã³ã³ã»ããïŒåå è
å
šäœããã補è¬äŒæ¥ã®ãããžã§ã¯ãã¡ã³ããŒãšä»®å®ãïŒæ¶ç©ºã®äºäŸã«ã€ããŠããããœã¢ãã³ã«é¢ãããªã¹ã¯ã¢ã»ã¹ã¡ã³ãã®å®æœæ¹æ³ãåè°ããïŒDSãšDPã§ãããã1hçšåºŠïŒ
é²ãæ¹ïŒ
èšè°çšè³æïŒEFPIAã®ã¯ãŒã¯ãããŒã®è³ªåå¥ã«ãŸãšããFAQïŒããè°è«ããã質åãéžæããã
è°é¡ã«é¢ããŠã©ããã£ãã¢ãããŒããé©åãåè°ãããç©æ¥µçã«æèŠãåºãåããè€æ°ã®æèŠãåŸãããå Žåã¯æèŠãåæãããåçãçµã蟌ãå¿
èŠã¯ãªããïŒæèŠãæ¯èŒããŠã¡ãªãããšãã¡ãªãããæ確ã«ããããšã¯éèŠããã¡ã·ãªããŒã¿ãŒã質åããŠè©³ããæãäžãããšããããŸãïŒå¿
èŠã«å¿ããŠïŒé¢é£ããå¥ã®è°è«ã«æ¡åŒµããŠãããã
æèŠããŸãšãããïŒç®æ¡æžãçšåºŠã§ç°¡åã«ãŸãšããïŒ
æéãç¡ããªããŸã§1~3ãç¹°ãè¿ãã
çºè¡š
èšè°çšè³ææ¡
ããããœã¢ãã³ã®ãªã¹ã¯è©äŸ¡èšè°_DPçš.pdf (783.7 KB)
ããããœã¢ãã³ã®ãªã¹ã¯è©äŸ¡èšè°_DSçš.pdf (726.3 KB)
ããããçæ§ã®ãšããã«ããé£çµ¡ãããããšåããŸããããã²ãšãååãã«åå ã®ãæ€èšããããããé¡ãããããŸãã
Tokumei
February 4, 2023, 6:03pm
45
@Yosukemino
2022/10ã®å€ç°ååŠäŒã§ã®ãã¬ãŒã³è³æãè±èš³ããã®ã§ãäœãã«äœ¿ã£ãŠãã ãããè±èš³ã®ç²ŸåºŠã«ã¯è²¬ä»»ã¯æãŠãŸãããã»ã»ã»ã
The comparison of nitrosamine guidance.pdf (2.8 MB)
3 Likes
@Tokumei
ããããšãããããŸããå©ãããŸãã
æ¥æ¬ã®çæ§
2/2ã«ç¡äºãªã³ã©ã€ã³èšè°ãçµããããšãã§ããŸãããå
çºåãšGEã¡ãŒã«ãŒåãããŠ15瀟以äžã30å以äžã®å°é家ãåå ããåè¬ã»è£œå€ã«é¢ããããããœã¢ãã³ã®æ§ã
ãªèª²é¡ã«ã€ããŠèšè°ããŸãããèšè°åŸã«ã¢ã³ã±ãŒã調æ»ãè¡ã£ãã®ã§ãããçŸæç¹ã§åçããã ããŠããå
šãŠã®æ¹ãã次åãåå ããããšããåçãããã ããŠãããŸããæ¬åœã«ããããéãã§ãããã¡ããåããŠæ¬¡åãéå¬äºå®ã§ãã
ç¹ã«æ¥æ¬åœå
ç¹æã®äºæ
ãšããŠã補é æ¥è
ãå
è£
è³æã»è©Šè¬ã»æ·»å å€ã¡ãŒã«ãŒãšãã£ãé¢é£äŒæ¥ããã®æ
å ±ãåŸãã®ãé£ããå Žåããããšããããšãå
±æã§ããŸãããç°¡åã«è§£æ±ºã§ããåé¡ã§ã¯ãªãã§ãããç²ã匷ãåãçµãå¿
èŠãããããã§ããããèšè°ã«ã€ããŠè©³çŽ°ãèããããšã®èŠæãããã°ããé æ
®ãªã@Yosukemino ãŸã§ãåãåãããã ããã
1 Like
ããã«ã¡ãã
ã¢ã³ã±ãŒã調æ»ã®åãæ±ãã«ã€ããŠä»¥äžã®ã¹ã¬ãããåèã«ãªã£ãã®ã§ããªã³ã¯ã貌ããŸããã確èªãããããé¡ãããããŸãã
IPEC Europe announces the availability of the revised âQuestionnaire for Excipient Nitrosamines Risk Evaluationâ (Version 4, 2022) . First published in December 2019 and updated in 2021, the Questionnaire has proven useful to excipient producers and MAHs.
This version is updated to remain contemporary with the EMA Q&A on Nitrosamines and clarifies that excipient manufacturers are not required to conduct a nitrosamine risk assessment without specific knowledge of the actual and specific drug proâŠ
1 Like
æ¥æ¬ã®çæ§ãããã«ã¡ãã
3/2ã«ç¡äºïŒåç®ã®ãªã³ã©ã€ã³èšè°ãçµããããšãã§ããŸãããåå è
ã¯ååãšåããããã§ãããããå
çº/GEã¡ãŒã«ãŒããå°é家ãåå ããåè¬ã»è£œå€ã«é¢ããããããœã¢ãã³ã®æ§ã
ãªèª²é¡ã«ã€ããŠåèš2æéã®èšè°ãããŸãããä»åã®è°é¡ã«ã€ããŠã以äžã«ç°¡åã«ãŸãšããŸãã
ã¡ãŒã«ã§ã®è³ªååéã®çµæå ±å
以äžã®Q1ïœQ3ã«ã€ããŠãä»ã®åå è
ããåŸãããåçãå ±åããè¿œå ã®è°è«ãè¡ã£ãã
Q1. Amesè©Šéšã®é°æ§çµæã ãã§ã¯åœå±ã«åãå
¥ããŠããããªããšã®ããšã ãããã®å Žåã¯åŠäœã«è©äŸ¡ãã¹ããïŒ
Q2. αäœã«æ°ŽçŽ ãæããªãããããœã¢ãã³ã®èš±å®¹é床å€ãåŠäœã«èšå®ãã¹ããïŒ(Read-acrossæ³ã§NDPhã®78000ng/dayãçšããããšã¯å¯èœãïŒïŒ
Q3. ãããŒã«ãã€ã³ããŒã«ã®ãããªããããµã€ã¯ãªãã¯ãªè³éŠæã¢ãã³ã«ç±æ¥ããããããœã¢ãã³ã«ã€ããŠãåŠäœã«ãªã¹ã¯è©äŸ¡ãã¹ããïŒ
ãŸãç¹ã«GEã¡ãŒã«ãŒã«ãããŠãèªç€Ÿå
ã«ååŠåæéšéããªããšã®çç±ãããNDSRIã®æšæºåãåæããããšãé£ãããšã®æèŠããã£ããå¿
èŠã«å¿ããŠè¡æ¿ãé¢é£äŒæ¥ãšæ
å ±å
±æããã
ææ°æ
å ±ã®å
±æ
第ïŒåNIOG-Industry meetingãããβãããã«ãŒã®NDSRIæ··å
¥ã«é¢ããã¢ãã«èšç®ãšMedicine for Europeã®Step2ã®çŸç¶ã«ã€ããŠç¢ºèªãããNDSRIã®é床å€ã®äœããããã¯ã«ãªã£ãŠå瀟察å¿ã«èŠåŽããŠããæ§åãèªã¿åããã
äºäŸã®å
±æ
äºçŽã¢ãã³ã®å¡©é
žå¡©ã§ããåè¬ããžã§ãããã«ã§ç²ç ããéã«ã倧æ°äžã®NOxã¬ã¹ã«ç±æ¥ããŠNDSRIã18ng/dayå以äžå¢ããäºäŸã«ã€ããŠå ±åãç¹æ®ãªæ¡ä»¶ã§ã®ç²ç ã§ã¯ãªãã£ãããšãããäºçŽã¢ãã³ã®ããããœåèœã®é«ãã瀺ãããäºäŸãšèãããèŠæ³šæã
åè¬ã®ãªã¹ã¯è©äŸ¡
Q25. 26. ããããœã¢ãã³ã蚱容é床å€ãè¶
ããªãéã§æ··å
¥ããå Žåã®ãã¹ãããè©Šéšãšå
šæ°è©Šéšã®äœ¿ãåããã©ããã¹ããïŒ
å ±åè
ã®äºäŸã§ã¯åè¬äžã®æ®çã¢ããéãšè£œå€äžã®ããããœã¢ãã³ã®çæéã«çžé¢ããã£ãããšãããRoot causeãæ確ã«ããŠé å¥ãªç®¡çæŠç¥ãèšå®ããã°ãã¹ãããè©Šéšã®é©çšã¯å¯èœãšã®çµè«ãšãªã£ãã
補å€ã®ãªã¹ã¯è©äŸ¡
Q44. åè¬ã®äžçŽç©ãäºçŽã¢ãã³ã§ããå Žåããªã¹ã¯è©äŸ¡ã察象ãšããéŸå€ãåŠäœã«èšå®ãã¹ããïŒ
æè¿çºåºãããæç®ãåèã«ãäžçŽç©éã§ããã°åé¡ãªããšã®çµè«ã«è³ã£ãããã ããpHãã¢ãã³ã®pKaãã¢ãã³ãšäºç¡é
žã®æ¿åºŠçã®åçš®æ¡ä»¶ã«æ³šæããã
è°è«ã®è©³çŽ°ã«ã€ããŠã¯@Yosuke MinoãŸã§ãååããã ããã
1 Like
Thanks for sharing @Yosukemino . Could you help to let us know what is the final outcome of discussions on Q1, 2 & 3?
Thank you for asking questions, @Pradpharma . I add the excerpt from the minutes as follows;
Q1:
âReplies from 3 companies.
âIn summary, evaluation methods other than the Ames test for unknown nitrosamines have not been clearly defined in the guidance now. The details will be determined in the future.
âAccording to the results of FDA research, the reactivity of nitrosamine Ames tests can vary greatly depending on differences in S9 between rats and hamsters, and differences in S9 amounts. Unless the method is at least optimized, the authorities canât adopt it alone, can they?
Q2:
âReplies from 2 companies.
âIf the nitrosamine sample is available, the Ames test of it may show negative. (By the way, NDPh is weakly carcinogenic due to nitroso transfer but is negative for normal Ames test)
â78,000 ng/day in Read-Across may apply to a product with two aromatic rings directly connected to nitrogen, like NDPh. There was a company that adopted the same approach as above.
Q3:
âReplies from 2 companies.
âBased on the information such as nitrogen has no basicity, there are no cases of recall for NDSRI with heterocyclic aromatic amines except for nitroso irbesartan, and metabolic activity via ring opening can not occur, it will probably be out of scope.
âA compound without basicity is not considered an amine. And it is a simple nitroso compound. However, it is suspected to be structurally mutagenic. It should be controlled under ICH M7 if the final product will be contaminated with it.
And you can find several similar topics in this community.
2 Likes